Rimegepant, sold under the brand name Nurtec ODT among others, is a medication used for the acute treatment of migraine with or without aura in adults and the prophylactic/ preventive treatment of episodic migraine in adults. It is taken by mouth to dissolve on the tongue as an orally disintegrating tablet. Rimegepant is a small-molecule calcitonin gene-related peptide receptor antagonist in the gepant class that selectively binds the CGRP receptor to block CGRP-mediated vasodilation and neurogenic inflammation implicated in migraine pathophysiology. Clinically relevant pharmacokinetic characteristics include rapid oral absorption with peak plasma concentrations typically within about 1 to 2 hours, an elimination half-life on the order of 11 hours, and metabolism primarily via CYP3A4 with minor involvement of CYP2C9; renal and biliary routes account for excretion of parent and metabolites. The drug has minimal vasoconstrictive activity compared with 5-HT1B/1D agonists and is formulated as an orally disintegrating tablet to allow administration without water when needed.
Parent: Rimegepant
Parent: Rimegepant
Parent: Rimegepant
Parent: Rimegepant
Parent: Rimegepant
Parent: Rimegepant
Parent: Rimegepant
![(5S,6S,9R)-5-amino-6-(2-fluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin- 9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate](https://veeprho.com/wp-content/uploads/2022/08/5S-6S-9R-5-amino-6-2-fluorophenyl-6-7-8-9-tetrahydro-5H-cyclohepta5Bb5Dpyridin-9-yl204-2-oxo-2-3-dihydr.png "(5S,6S,9R)-5-amino-6-(2-fluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin- 9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate")
Parent: Rimegepant
![(5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ol](https://veeprho.com/wp-content/uploads/2022/07/5S6S9R-5-amino-6-23-difluorophenyl-6789-tetrahydro-5H-cycloheptabpyridin-9-ol.png "(5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ol")
Parent: Rimegepant
![1-(1-(1H-imidazole-1-carbonyl)piperidin-4-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one](https://veeprho.com/wp-content/uploads/2023/04/1-1-1H-imidazole-1-carbonyl-piperidin-4-yl-1H-imidazo-4-5-b-pyridin-2-3H-one.png "1-(1-(1H-imidazole-1-carbonyl)piperidin-4-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one")
Parent: Rimegepant
![1-(1-nitrosopiperidin-4-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one](https://veeprho.com/wp-content/uploads/2025/05/VE0023846-1-1-nitrosopiperidin-4-yl-1H-imidazo4-5-b-pyridin-2-3H-one.png "1-(1-nitrosopiperidin-4-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one")
Parent: Rimegepant
![1-(piperidin-4-yl)-1,3-dihydro-2H-imidazo [4,5-b]pyridin-2-one](https://veeprho.com/wp-content/uploads/2022/08/1-piperidin-4-yl-1-3-dihydro-2H-imidazo-4-5-b-pyridin-2-one.png "1-(piperidin-4-yl)-1,3-dihydro-2H-imidazo [4,5-b]pyridin-2-one")
Parent: Rimegepant
![1-(piperidin-4-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one](https://veeprho.com/wp-content/uploads/2023/04/1-piperidin-4-yl-1H-imidazo-4-5-b-pyridin-2-3H-one.png "1-(piperidin-4-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one")
Parent: Rimegepant
Impurity control for rimegepant covers process-related impurities, degradation products from stress conditions, residual solvents and elemental impurities, and specified related compounds arising from synthesis and purification. Typical quality specifications follow global regulatory guidance and limit individual known related compounds to low parts per thousand or parts per ten thousand ranges, often controlled to about 0.05 to 0.20 percent by weight for specified impurities and with total impurities maintained below approximately 1.0 percent by weight depending on the manufacturer specification; unspecified impurities are typically controlled at tighter reporting and identification thresholds. Residual solvents are limited according to ICH Q3C classifications and elemental impurities are controlled per ICH Q3D. Analytical methods commonly used for profiling include HPLC with UV or MS detection, LC-MS for identification of unknowns, and forced-degradation studies to define degradants for shelf life and stability programs.
Rimegepant is a small-molecule CGRP receptor antagonist in the gepant class indicated for acute treatment of migraine attacks and for preventive treatment of episodic migraine in adults; it is an orally disintegrating tablet formulation.
Rimegepant binds selectively to the calcitonin gene-related peptide receptor and blocks CGRP signaling, reducing CGRP-driven vasodilation and neurogenic inflammation that contribute to migraine pain and associated symptoms.
Common adverse events reported in clinical studies include nausea, somnolence and dry mouth; most events are mild to moderate. Rimegepant has not been associated with the vasoconstrictive effects seen with triptans, but hepatic and hypersensitivity reactions are monitored in postmarketing surveillance. Clinically relevant drug interactions can occur with strong CYP3A4 inhibitors or inducers.
No, Sumatriptan is a triptan that acts as a 5-HT1B/1D receptor agonist and exerts migraine relief in part through cranial vasoconstriction. Rimegepant is a CGRP receptor antagonist and does not cause the same vasoconstrictive action, so their mechanisms, safety profiles and some clinical considerations differ.
